TY - JOUR
T1 - Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER)
AU - Ridker, Paul M
AU - MacFadyen, Jean G
AU - Fonseca, Francisco A H
AU - Genest, Jacques
AU - Gotto, Antonio M
AU - Kastelein, John J P
AU - Koenig, Wolfgang
AU - Libby, Peter
AU - Lorenzatti, Alberto J
AU - Nordestgaard, Børge
AU - Shepherd, James
AU - Willerson, James T
AU - Glynn, Robert J
AU - JUPITER Study Group
AU - Ridker, Paul M
AU - MacFadyen, Jean G
AU - Fonseca, Francisco A H
AU - Genest, Jacques
AU - Gotto, Antonio M
AU - Kastelein, John J P
AU - Koenig, Wolfgang
AU - Libby, Peter
AU - Lorenzatti, Alberto J
AU - Nordestgaard, Børge G
AU - Shepherd, James
AU - Willerson, James T
AU - Glynn, Robert J
AU - JUPITER Study Group
N1 - Keywords: Age Factors; Body Mass Index; C-Reactive Protein; Cholesterol, LDL; Continental Population Groups; Double-Blind Method; Endpoint Determination; Female; Fluorobenzenes; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome X; Myocardial Infarction; Myocardial Revascularization; Primary Prevention; Pyrimidines; Risk Factors; Stroke; Sulfonamides
PY - 2009/11/1
Y1 - 2009/11/1
N2 - BACKGROUND: As recently demonstrated, random allocation to rosuvastatin results in large relative risk reductions for first cardiovascular events among apparently healthy men and women with low levels of low-density lipoprotein cholesterol but elevated levels of high-sensitivity C-reactive protein. However, whether the absolute risk reduction among such individuals justifies wide application of statin therapy in primary prevention is a controversial issue with broad policy and public health implications. METHODS AND RESULTS: Absolute risk reductions and consequent number needed to treat (NNT) values were calculated across a range of end points, timeframes, and subgroups using data from Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), a randomized evaluation of rosuvastatin 20 mg versus placebo conducted among 17 802 apparently healthy men and women with low-density lipoprotein cholesterol <130 mg/dL and high-sensitivity C-reactive protein >or=2 mg/L. Sensitivity analyses were also performed to address the potential impact that alternative statin regimens might have on a similar primary prevention population. For the end point of myocardial infarction, stroke, revascularization, or death, the 5-year NNT within JUPITER was 20 (95% CI, 14 to 34). All subgroups had 5-year NNT values for this end point below 50; as examples, 5-year NNT values were 17 for men and 31 for women, 21 for whites and 19 for nonwhites, 18 for those with body mass index 300). CONCLUSIONS: Absolute risk reductions and consequent NNT values associated with statin therapy among those with elevated high-sensitivity C-reactive protein and low low-density lipoprotein cholesterol are comparable if not superior to published NNT values for several widely accepted interventions for primary cardiovascular prevention, including the use of statin therapy among those with overt hyperlipidemia. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov. Identifier NCT00239681.
AB - BACKGROUND: As recently demonstrated, random allocation to rosuvastatin results in large relative risk reductions for first cardiovascular events among apparently healthy men and women with low levels of low-density lipoprotein cholesterol but elevated levels of high-sensitivity C-reactive protein. However, whether the absolute risk reduction among such individuals justifies wide application of statin therapy in primary prevention is a controversial issue with broad policy and public health implications. METHODS AND RESULTS: Absolute risk reductions and consequent number needed to treat (NNT) values were calculated across a range of end points, timeframes, and subgroups using data from Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), a randomized evaluation of rosuvastatin 20 mg versus placebo conducted among 17 802 apparently healthy men and women with low-density lipoprotein cholesterol <130 mg/dL and high-sensitivity C-reactive protein >or=2 mg/L. Sensitivity analyses were also performed to address the potential impact that alternative statin regimens might have on a similar primary prevention population. For the end point of myocardial infarction, stroke, revascularization, or death, the 5-year NNT within JUPITER was 20 (95% CI, 14 to 34). All subgroups had 5-year NNT values for this end point below 50; as examples, 5-year NNT values were 17 for men and 31 for women, 21 for whites and 19 for nonwhites, 18 for those with body mass index 300). CONCLUSIONS: Absolute risk reductions and consequent NNT values associated with statin therapy among those with elevated high-sensitivity C-reactive protein and low low-density lipoprotein cholesterol are comparable if not superior to published NNT values for several widely accepted interventions for primary cardiovascular prevention, including the use of statin therapy among those with overt hyperlipidemia. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov. Identifier NCT00239681.
U2 - 10.1161/CIRCOUTCOMES.109.848473
DO - 10.1161/CIRCOUTCOMES.109.848473
M3 - Journal article
C2 - 20031900
SN - 1941-7713
VL - 2
SP - 616
EP - 623
JO - Circulation: Cardiovascular Quality and Outcomes
JF - Circulation: Cardiovascular Quality and Outcomes
IS - 6
ER -
